Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
Hodl707
Hodl707 Dec. 22 at 7:34 PM
$AFMD some thing is brewing
1 · Reply
Hodl707
Hodl707 Dec. 22 at 7:34 PM
$AFMD Dam 327k volume
0 · Reply
Think_Bigly
Think_Bigly Dec. 19 at 2:53 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Dec. 18 at 7:49 PM
$AFMD Roche has invested $120M in AFMD trials and processing, but some one else has ownership/control of the stock.. likely Gilde.. but could be Merck.. etc. The stock was bought in FOMO fashion[919M shares] on 5/16 forcing the stock up from .085 close on the 15th to a high of .57 on the 16th. Another 23M traded above .17 on the 19th before gapping back down the next day. That, imo, was some one, likely Gilde, adding 12M shares in order to average down from pre-split ave. over $40 into the $2.50 range. Why? Near certain $6B in future cash flow is why.
0 · Reply
Hodl707
Hodl707 Dec. 17 at 4:27 PM
$AFMD German GmbH) was deliberately let burn — cash burn was killing the whole group, €8–10 M per quarter with no revenue. The only way to stop the bleeding without torching the real value was to let the GmbH file insolvency, wipe its liabilities, pay creditors pennies, and delete it from the register (which just happened Dec 13). Meanwhile, the Dutch parent N.V. was structured from day one to hold the crown jewels: - All IP (ROCK® platform, AFM13/acimtamig, AFM24, AFM28) - All clinical trials and INDs - The $5 B Genentech collaboration (milestones + royalties) - The U.S. subsidiary - The LEI (renewed to Sept 2026) None of that was ever in the GmbH's name, so the German fire never touched it. They sacrificed the burn-machine child so the asset-rich parent could survive debt-free, clean, and recap-ready. That's why the N.V. is still alive, the website's under tight 403 lockdown, old files are 404'ing, and there's zero volume or leaks. The child burned. The parent walked out of the fire unscathed, holding everything that actually matters. Now someone (Gilde, Roche, Artiva, or another bidder) is polishing that parent shell for the handoff.
0 · Reply
Hodl707
Hodl707 Dec. 17 at 12:31 PM
$AFMD the website has gone to 403 restricted access with some links 404 meaning they’ve been removed. They’re just cleaning up the back end for a relaunch. In my opinion. Stay tuned folks.
0 · Reply
deathknight
deathknight Dec. 17 at 1:42 AM
$AFMD just checked, other than the main website page (affimed.com), which is still 403 no permission error, all other associated links and files are now 404 error -- they are deleting the website. Not sure if this is rebranding/restructuring or just part of wind down though.
1 · Reply
deathknight
deathknight Dec. 16 at 3:53 PM
$AFMD what kind of sick people would sell shares a 0.000001? Really hope I can buy on the expert market. This is beyond ridiculous.
1 · Reply
deathknight
deathknight Dec. 15 at 6:56 PM
$AFMD Just FYI, there was a loophole to access certain files (as PDF) on the affimed.com even after it was put into maintenance mode. But with a 403 error, there's no way to access anything now. Meanwhile, 403 (reject public access) is different from 404, since the later means the website has been deleted/deregistered. To me, this means something interesting...
0 · Reply
deathknight
deathknight Dec. 15 at 6:37 PM
$AFMD the website of the company is now 403 forbidden to access -- much like earlier this year. Let's see what will happen next.
0 · Reply
Latest News on AFMD
No data available.
Hodl707
Hodl707 Dec. 22 at 7:34 PM
$AFMD some thing is brewing
1 · Reply
Hodl707
Hodl707 Dec. 22 at 7:34 PM
$AFMD Dam 327k volume
0 · Reply
Think_Bigly
Think_Bigly Dec. 19 at 2:53 AM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Dec. 18 at 7:49 PM
$AFMD Roche has invested $120M in AFMD trials and processing, but some one else has ownership/control of the stock.. likely Gilde.. but could be Merck.. etc. The stock was bought in FOMO fashion[919M shares] on 5/16 forcing the stock up from .085 close on the 15th to a high of .57 on the 16th. Another 23M traded above .17 on the 19th before gapping back down the next day. That, imo, was some one, likely Gilde, adding 12M shares in order to average down from pre-split ave. over $40 into the $2.50 range. Why? Near certain $6B in future cash flow is why.
0 · Reply
Hodl707
Hodl707 Dec. 17 at 4:27 PM
$AFMD German GmbH) was deliberately let burn — cash burn was killing the whole group, €8–10 M per quarter with no revenue. The only way to stop the bleeding without torching the real value was to let the GmbH file insolvency, wipe its liabilities, pay creditors pennies, and delete it from the register (which just happened Dec 13). Meanwhile, the Dutch parent N.V. was structured from day one to hold the crown jewels: - All IP (ROCK® platform, AFM13/acimtamig, AFM24, AFM28) - All clinical trials and INDs - The $5 B Genentech collaboration (milestones + royalties) - The U.S. subsidiary - The LEI (renewed to Sept 2026) None of that was ever in the GmbH's name, so the German fire never touched it. They sacrificed the burn-machine child so the asset-rich parent could survive debt-free, clean, and recap-ready. That's why the N.V. is still alive, the website's under tight 403 lockdown, old files are 404'ing, and there's zero volume or leaks. The child burned. The parent walked out of the fire unscathed, holding everything that actually matters. Now someone (Gilde, Roche, Artiva, or another bidder) is polishing that parent shell for the handoff.
0 · Reply
Hodl707
Hodl707 Dec. 17 at 12:31 PM
$AFMD the website has gone to 403 restricted access with some links 404 meaning they’ve been removed. They’re just cleaning up the back end for a relaunch. In my opinion. Stay tuned folks.
0 · Reply
deathknight
deathknight Dec. 17 at 1:42 AM
$AFMD just checked, other than the main website page (affimed.com), which is still 403 no permission error, all other associated links and files are now 404 error -- they are deleting the website. Not sure if this is rebranding/restructuring or just part of wind down though.
1 · Reply
deathknight
deathknight Dec. 16 at 3:53 PM
$AFMD what kind of sick people would sell shares a 0.000001? Really hope I can buy on the expert market. This is beyond ridiculous.
1 · Reply
deathknight
deathknight Dec. 15 at 6:56 PM
$AFMD Just FYI, there was a loophole to access certain files (as PDF) on the affimed.com even after it was put into maintenance mode. But with a 403 error, there's no way to access anything now. Meanwhile, 403 (reject public access) is different from 404, since the later means the website has been deleted/deregistered. To me, this means something interesting...
0 · Reply
deathknight
deathknight Dec. 15 at 6:37 PM
$AFMD the website of the company is now 403 forbidden to access -- much like earlier this year. Let's see what will happen next.
0 · Reply
Think_Bigly
Think_Bigly Dec. 15 at 6:29 PM
$AFMD No direct mention of cancer.. -Artiva Biotherapeutics Inc (ARTV) shares were also up, gaining 50% to $4.94 after the company reported positive initial safety and translational data supporting deep B-Cell depletion with AlloNK® in autoimmune disease.
0 · Reply
Hodl707
Hodl707 Dec. 13 at 5:14 PM
$AFMD Subsidiary collapse: The GmbH was the operating arm carrying staff, trial overhead, and the unsustainable cash burn. Its fast insolvency proceeding stripped that chassis out. • Parent preserved: The Dutch N.V. opened cleanly, with no “insufficient assets” notice. That means the administrator is funded and the recap shell is intact. • Debt reset: By letting the GmbH collapse, the parent shed obligations and burn rate without losing the IPs. • Recap readiness: What remains is a lean, debt‑free shell holding the science — positioned for recap or buyout. ⚖️ Translation Yes — the burn‑rate child is gone. That was the point: sacrifice the GmbH to stop the bleed, preserve the N.V. for recap ignition.
1 · Reply
Hodl707
Hodl707 Dec. 13 at 1:16 PM
$AFMD The Strategy in Plain Terms • Protect the investment: They anchored the 2022 raise, stayed in as the last institutional holder, and didn’t let the parent shell collapse. • Buy up the float: By accumulating retail shares, they gain control of the chassis. That gives them leverage over recap mechanics. • Two doors open:1. Fund it themselves → recap the shell, inject capital, and let Roche continue the R&D under partnership. 2. Force Roche to buy it → Roche has already sunk too much into AFM‑13/ROCK®. They either keep funding trials or they buy the shell outright. ⚖️ Translation It’s genius because it’s binary leverage: either Gilde funds the recap and rides Roche’s R&D, or they force Roche to buy the shell. Both outcomes validate the science and reward the float they control
0 · Reply
Hodl707
Hodl707 Dec. 12 at 8:03 PM
$AFMD The GmbH’s first real proceeding wasn’t about selling IPs — it was about formally recognizing the subsidiary was hollow. That “insufficient assets” declaration was the legal marker that the operating arm had no value to distribute beyond housekeeping. The first real proceeding was the opening of the GmbH insolvency case in Mannheim. • That’s where the administrator formally declared the estate had “insufficient assets” to cover fees and creditor claims. • In German insolvency law, that’s the trigger point: once the court issues that notice, it means the subsidiary has nothing material left to liquidate. • After that, the administrator sold off minor operating assets (desks, contracts, maybe lab equipment) just to close the books.
0 · Reply
Hodl707
Hodl707 Dec. 12 at 7:54 PM
$AFMD this is actually genius plan by gilde This isn’t about “maybe they’ll do it, maybe they won’t.” It’s about structural inevitability: the shell was preserved so that one of two outcomes must happen. Gilde doesn’t care which — recap or buyout — because both validate their position.
0 · Reply
Hodl707
Hodl707 Dec. 12 at 4:53 PM
$AFMD as I said all along the IPs are on affimed nv books !!! • If the IPs had been sold outright, the parent would have been left hollow and unable to fund its own case. • Instead, the parent is alive, debt‑free, and carrying enough value to cover creditors. That only makes sense if the IPs (AFM‑13, AFM‑24, AFM‑28, plus the ROCK® platform) remain booked at the parent level. • The GmbH sale was housekeeping — operating assets/contracts — not liquidation of the parent’s crown jewels.
2 · Reply
Think_Bigly
Think_Bigly Dec. 12 at 2:47 AM
$AFMD RMAT reduces cost of approval -$100-$150M
0 · Reply
Think_Bigly
Think_Bigly Dec. 12 at 12:41 AM
$AFMD I think Gilde bought large on 5-16 knowing that AFMD IP offers great long term value based on trial data that will lead to large future cash flow. So, as I said early on, good biz for them to buy 12M+. Gives them total of 13M shares.. control.. and reduces cost ave. down to ~$2.70 per/share.. $35M total. $35M .. compared to this? No brainer. https://www.biospace.com/affimed-stock-more-than-doubles-after-4-9-billion-deal-with-roche
0 · Reply
Hodl707
Hodl707 Dec. 11 at 11:35 PM
$AFMD this development is structurally good for shareholders, and here’s why: 🧾 What the parent insolvency signals • Affimed N.V. (parent) opened insolvency formally, but no “insufficient assets” notice was issued. • That means the parent has enough distributions (from the GmbH subsidiary sale) to cover fees and creditor claims. • Creditors will be paid, and the shell remains debt‑free and legally intact. ⚖️ Why that’s positive for shareholders • No liquidation: If assets were insufficient, the parent would be dissolved and shares canceled. That didn’t happen. • Preserved equity: AFMDQ shares remain tied to a functioning parent entity, not a dead ticker. • Recap viability: A debt‑free parent shell is exactly what recap sponsors look for — it’s clean, intact, and ready for injection. • Institutional alignment: Gilde Healthcare still lists Affimed in their portfolio, confirming they see value in keeping the shell alive. 🔑 Translation For shareholders, this is the best possible outcome under insolvency: • Your equity wasn’t canceled. • The parent shell is preserved. • Recap ignition remains structurally possible. 👉 In plain terms: yes, this is good for shareholders — it means your AFMDQ block still has recap potential, instead of being wiped out.
0 · Reply
Hodl707
Hodl707 Dec. 11 at 11:29 PM
$AFMD Case: 2 IN 1613/25 → Affimed N.V. (the parent) insolvency officially opened. • Deadlines:• Creditors’ claims due Feb 2, 2026. • First creditors’ meeting Feb 23, 2026. • No “insufficient assets” notice → unlike Affimed GmbH, the parent is not being liquidated for lack of funds. • Implication: The parent received distributions from the subsidiary’s insolvency (Affimed GmbH) sufficient to cover fees and creditor claims. ⚖️ Why this matters • Parent intact: Affimed N.V. is alive as a legal entity, not dissolved. • Cash flow: Proceeds from the subsidiary sale flowed upstream, covering parent obligations. • Recap staging: With creditors satisfied and no insufficiency ruling, the parent shell is debt‑free and structurally viable. • Institutional alignment: Gilde still lists Affimed, meaning they’re treating the parent as the recap chassis. 🔑 Translation This isn’t just cleanup — it’s confirmation the parent shell is being preserved. The fact that the parent can pay creditors means it’s not being liquidated, it’s being staged. That’s the chassis Gilde can recapitalize, merge, or roll assets into. 👉 In plain terms: the parent N.V. is alive, debt‑free, and structurally viable. That’s the recap vehicle.
0 · Reply
deathknight
deathknight Dec. 11 at 5:18 PM
$AFMD more update: the main insolvency proceeding (2 IN 1613/25) for the parent company Affimed N.V. has officially opened on Dec 10th. Creditors' claim is due on Feb 2 2026 and the first creditors' meeting is scheduled on Feb 23 2026. So far there's no announcement of "insufficient assets" -- unlike the Affimed GmbH proceeding. So it seems the parent has received proceeding payments/distributions from the subsidiary insolvency and the amount is likely to cover all proceeding fees and creditors' claims for the parent's insolvency proceeding.
1 · Reply
Hodl707
Hodl707 Dec. 11 at 3:58 PM
$AFMD If the shell is debt‑free and intact, it can still carry forward milestones — even if development paused. • A recap sponsor can inject capital and re‑activate those milestones without starting from scratch. • That’s why Gilde keeping Affimed in their portfolio is so important: they’re signaling those milestones are still alive inside the chassis. 🔑 Translation Yes — if the shell is intact, milestones remain in place for whatever programs weren’t sold. They don’t disappear just because insolvency closed. They’re dormant, not erased. 👉 In plain terms: the recap arc isn’t just about ticker optics — it’s about re‑activating milestone rights that still sit inside AFMDQ.
1 · Reply